NeuroThera Labs Acquires Majority Stake in CliniQuantum, Merging Quantum Computing with Clinical Trials
NeuroThera Labs Inc. has closed its acquisition of a 54.01% stake in CliniQuantum Ltd., aiming to enhance clinical trial precision through quantum simulation and Monte Carlo methods.
NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced today the closing of its acquisition of a 54.01% stake in CliniQuantum Ltd., an Israeli technology firm specializing in quantum simulation for clinical trial data analysis. The transaction, valued at approximately $9.46 million, was completed through the issuance of 56.6 million common shares to the selling shareholders, with no cash consideration paid.
Under the share purchase agreement, originally dated March 9, 2026, and amended on April 30, 2026, NeuroThera acquired 56,375 ordinary shares of CliniQuantum. The selling shareholders may also receive earn-out payments of up to US$2.5 million, contingent on milestones such as patent filings and fundraising targets, payable over three years. Additionally, the company issued 2,829,999 finder’s shares to arm’s length parties in connection with the transaction.
CliniQuantum’s platform applies quantum simulation and quantum Monte Carlo methods to clinical trial data, aiming to identify patient subpopulations that respond to investigational therapies. This acquisition positions NeuroThera to leverage quantum technologies in the life sciences sector, complementing its existing focus on central nervous system disorders. The integration of quantum computing into clinical trials could significantly improve the precision of outcomes, potentially reducing trial sizes and accelerating drug development timelines.
The deal involves a non-arm’s length relationship, as Amitay Weiss, a director of SciSparc Ltd. and its nutraceutical subsidiary, also serves on the board of Quantum X Labs Ltd., which holds the remaining 45.98% of CliniQuantum shares. The transaction was classified as a reviewable transaction under TSX Venture Exchange policies but did not constitute a related party transaction under Multilateral Instrument 61-101. All necessary corporate approvals and final TSXV acceptance were obtained prior to closing.
The consideration shares are subject to an escrow agreement, with staggered releases over 36 months: 10% at closing, followed by 15% every six months thereafter. Additionally, the shares carry a statutory hold period of four months and one day, expiring October 2, 2026. This structure aligns the interests of selling shareholders with NeuroThera’s long-term performance.
For NeuroThera, this acquisition represents a strategic move into quantum-enhanced analytics, a field with growing applications in biotech. By harnessing CliniQuantum’s technology, the company aims to improve the efficiency and accuracy of its clinical programs, potentially leading to faster regulatory approvals and better patient outcomes. The broader implications for the industry include a shift toward data-driven trial designs that could reduce costs and increase success rates in drug development.
The company’s forward-looking statements caution that actual results may differ materially due to risks including CliniQuantum’s early stage, reliance on licensed technology, and market uncertainties. Further details are available in NeuroThera’s continuous disclosure documents on SEDAR+.